Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents

Author(s): Bontha Venkata Subrahmanya Lokesh*, Y. Rajendra Prasad and Afzal Basha Shaik

Volume 19, Issue 3, 2019

Page: [310 - 321] Pages: 12

DOI: 10.2174/1871526519666181217120626

Price: $65

Abstract

Background: Many synthetic procedures were reported till date to prepare pyrazoline derivatives. Some have published pyrazolines from different chalcone derivatives in the literature.

Objective: A series of new pyrazolines containing novel 2,5-dichloro-3-acetylthiophene chalcone moiety (PZT1-PZT20) have been synthesized, characterized by 1HNMR and 13CNMR and evaluated for them in vitro antitubercular activity against M. tuberculosis H37Rv strain and in vitro anticancer activity against DU-145 prostate cancer cell lines and all compounds were also screened for molecular docking studies against specific targeted protein domains.

Methods: All compounds were screened for potential activity against Mycobacterium tuberculosis H37Rv (MTB) strain and anticancer activity against DU-149 prostate cancer cell lines using MTT cytotoxicity assay.

Results: Among the series, compound PZT5 with 2”, 4”-dichlorophenyl group at 5-position on the pyrazoline ring exhibited the most potent antitubercular activity (MIC=1.60 µg/mL) and compounds PZT2, PZT9, PZT11, PZT15, and PZT20 showed similar antitubercular activity against standard pyrazinamide (MIC=3.12 µg/mL) by broth dilution assay. PZT15 and PZT17 with 4”- pyridinyl and 2”-pyrrolyl groups on pyrazoline ring were found to exhibit better anticancer activity against DU-149 prostate cancer cell lines with IC50 values of 2.0±0.2 µg/mL and 6.0±0.3 µg/mL respectively by MTT assay. The preliminary structure-activity relationship has been summarized. The molecular docking studies with crystalline structures of enoyl acyl carrier protein reductase InhA interaction with target protein (2NSD; PDB and 3FNG; PDB) of Mycobacterium tuberculosis H37Rv (MTB) strain have also exhibited good ligand interaction and binding affinity. Ligand interaction and binding affinity were estimated using crystal structures of both types of enoyl acyl carrier protein reductase InhA (3FNG.pdb) and found to be much higher (-16.70 to - 19.20 kcal/mol) compared with pyrazinamide (-10.70 kcal/mol) as a standard target molecule. Whereas the binding affinities of six active compounds with crystal structure of other type of enoyl acyl carrier protein reductase InhA (2NSD.pdb) were much similar and higher (-9.30 to - 11.20 kcal/mole) than pyrazinamide (-11.10 kcal/mole).

Conclusion: These new pyrazolines would be promising potent inhibitors of drug sensitive and drug resistant Mycobacterium tuberculosis strain and potential anticancer agents against prostate cancer and other prototypes of cancers.

Keywords: 2, 5-dichloro-3-acetylthiophene chalcone, pyrazolines, structure-activity relationship, M. tuberculosis H37Rv strain, antitubercular activity, cytotoxicity, prostate cancer.

Graphical Abstract

[1]
Maayan, S.; Ohad, N.; Soliman, K. Bioorg. Med. Chem., 2005, 13, 433.
[http://dx.doi.org/10.1016/j.bmc.2004.10.010] [PMID: 15598564]
[2]
Mark, C.; Nagarathnam, D. J. Nat. Prod., 1991, 54, 1656.
[http://dx.doi.org/10.1021/np50078a027] [PMID: 1812215]
[3]
Awasthi, S.K.; Mishra, N.; Kumar, B.; Sharma, M.; Bhattacharya, A.; Mishra, L.C.; Bhasin, V.K. Med. Chem. Res., 2009, 18, 407-420.
[http://dx.doi.org/10.1007/s00044-008-9137-9]
[4]
Lim, S.S.; Kim, H.S.; Lee, D.U. Bull. Korean Chem. Soc., 2007, 28, 2495-2497.
[http://dx.doi.org/10.5012/bkcs.2007.28.12.2495]
[5]
Lokesh, B.V.S.; Prasad, Y.R.; Shaik, A.B. Ind. J Pharm. Educ. Res., 2017, 51(4S), S679-S690.
[6]
Loudon, J.D.; Rodd, E.H. Elsevier Publishing Company New York, 1957, 4, 348-353.
[7]
Orlov, V.D.; Aziz, M.A. 2005, 18, p. 74.
[8]
Sammour, A.E.A. Tetrahedron, 1967, 20, 1067.
[http://dx.doi.org/10.1016/S0040-4020(01)98444-3]
[9]
Chase, B.H.; Evans, J.M. J. Chem. Soc., 1964, 4825.
[http://dx.doi.org/10.1039/jr9640004825]
[10]
Nisbet, H.B. J. Chem. Soc., 1945, 126.
[http://dx.doi.org/10.1039/JR9450000126]
[11]
Tselyutina, V.K.; Golovchenko, T.N.; Romadan, G.N.; Salova, R.A.; Kotomin, L.P. U.S.S.R patent, 1980, 775, p. 102.
[12]
Huisgen, A.R. Chem. Internet Edn, 1963, 2, 565.
[http://dx.doi.org/10.1002/anie.196305651]
[13]
Alexander, L.N.; Florence, E.C. J. Am. Chem. Soc., 1957, 79, 3831.
[http://dx.doi.org/10.1021/ja01571a056]
[14]
William, E.P.; Fredrick, D.B.; Donald, R.T. J. Org. Chem., 1962, 27, 2415.
[http://dx.doi.org/10.1021/jo01054a032]
[15]
Barlow, M.G.; Hazseldine, R.N.; Morton, W.D. Chemical Com-munication, 1965, 931.
[16]
Overberger, C.G.; Weinschenk, N.; Anselme, J.P. J. Am. Chem. Soc, 1965, 87, 4119.17.
[17]
Kalsi, P.S.; Chhabra, B.R.; Chhabra, A.; Wadia, M.S. Tetrahedron, 1979, 35, 1993.
[http://dx.doi.org/10.1016/0040-4020(79)85060-7]
[18]
Kost Grandberg, A.N.; Katritzky, A.R. Academic press: New York. , 1966, p. 6, p. 347.
[19]
Sagar, A.J.; Kiran, M.K.; Pramod, B.P.; Vikar, R.D.; Shita-kumar, S.P. Pharma Chem., 2016, 8(3), 38-45.
[20]
Rahman, S.A.; Rajendra Prasad, Y.; Bhuvaneswari, K. Kumar Phani. Int. J. Chemtech Res., 2010, 2(1), 16-20.
[21]
R. Kavitha M. Nagoor Meeran. R.P. Sureshjeykumar. Chem. Sci. Trans., 2015, 4(4), 1001-1006.
[22]
Levin, A. JozcefJeko. ARKIVOC, 2005, •••, 199-205.
[23]
Savita Upadhyay, C. Avinash. Tripathi, Sarvesh Paliwal, K. Shailendra. Saraf. Experimental and Clinical Sciences Journal, 2017, 16, 628-649.
[24]
Mishriky Nawal, F.M.; Ibrahim, Y.A.; Girgis, A.S.; Su, F. Pharmazie, 1996, 51, 544.
[PMID: 8794465]
[25]
Soliman, R.; Faid-Allah, H.M.; el-Sadany, S.K.; Samisk, E. Preparation and antidiabetic activity of new substituted 3,5-diarylpyrazolesulfonylurea derivatives. II: Structure-activity relationship. J. Pharm. Sci., 1987, 76(8), 626-632.
[http://dx.doi.org/10.1002/jps.2600760808] [PMID: 11002821]
[26]
Karabacak, M.; Altıntop, M.D.; İbrahim Çiftçi, H.; Koga, R.; Otsuka, M.; Fujita, M.; Özdemir, A. Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents. Molecules, 2015, 20(10), 19066-19084.
[http://dx.doi.org/10.3390/molecules201019066] [PMID: 26492233]
[27]
Bhat and A.Kumar. Asian J Pharm. Clin. Res. (Alex.), 2017, 10(6), 247-249.
[28]
Morris, G.M.; Lim-Wilby, M. Humana Press; , 2008.
[29]
ICH guidelines. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
[30]
Goto, S.; Jo, K.; Kawakita, T.; Misuhashi, S.; Nishino, T.; Ohasawa, N.; Tanami, H. 1981, 29, pp. 76-79.
[31]
Watts, J.L.; Lindeman, C.J. Antimicrobial Susceptibility Testing of Bacteria of Veterinary Origin , Aarestrup, FM., Ed.; ASM Press: Washington DC, USA Ch3. 2006.
[32]
Waisbren, C. Carr Dunette. J Am J Clin Pathol, 1951, 21, 884-887.
[33]
Shah, R.R.; Mehta, R.D.; Parikh, A.R. J. Indian Chem. Soc., 1985, 62, 255-260.
[34]
Wilson, A.P. 2000.
[35]
Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 1988, 48(3), 589-601.
[PMID: 3335022]

Rights & Permissions Print Cite
Article Metrics
57
2
© 2024 Bentham Science Publishers | Privacy Policy